Published online Nov 27, 2026. doi: 10.4254/wjh.125639
Revised: August 8, 2026
Accepted: October 16, 2026
Published online: November 27, 2026
Processing time: 129 Days and 10.8 Hours
Approximately 30% of adults worldwide have metabolic dysfunction-associated steatotic liver disease. The extent to which therapies that resolve steatosis preserve hepatocyte transcriptional identity beyond reducing lipid accumulation remains unclear.
To re-analyze bulk RNA-sequencing data from APOB-mutant human liver organoids treated for seven days with acetyl-CoA carboxylase inhibition, diacylglycerol acyltransferase 2 inhibition, fatty acid synthase inhibition, farnesoid X receptor agonism, or fibroblast growth factor 19 (GSE221705; 12 samples from two donors).
Analyses included DESeq2 differential expression analysis; three functional scores for steatosis modulation, hepatocyte identity, and stress-pathway responses; a weighted Therapeutic Trade-off Score; gene-level bootstrap confidence intervals; and exploratory single-cell contextualization of 3293 human hepatocytes from GSE136103.
Diacylglycerol acyltransferase 2 inhibition ranked first in the exploratory fra
These preliminary findings support diacylglycerol acyltransferase 2 inhibition as a potential metabolic dysfunction-associated steatotic liver disease strategy, but need to be validated in larger, clinically annotated cohorts given the limited sample size, post hoc signature selection, and single-cell pseudoreplication. This is deferred for future work.
Core Tip: This study presents a comprehensive transcriptomic framework to evaluate steatosis-targeting therapies by analyzing steatosis-related gene modulation, hepatocyte identity, cellular stress, and donor consistency, going beyond lipid reduction alone. Among the five therapies studied, diacylglycerol acyltransferase 2 inhibition demonstrated the most favorable relative exploratory profile. We further explored the association of the diacylglycerol acyltransferase 2 inhibition-derived signature with the transcriptional state of hepatocytes by exploratory single-cell analysis. However, these results remain hypothesis-generating due to the limited number of donors, the post hoc selection of signatures, and the pseudoreplication of single cells.